A Next-Gen Polymer Therapeutic

Our proprietary POZ platform is based on a synthetic, water soluble, low viscosity polymer called poly(2-oxazoline). During the synthesis steps, a predictable amount of drug is incorporated on the backbone of the polymer using pendant alkyne groups and metal catalyzed “click chemistry”.

POZ technology provides greater control in drug loading, and the rate of release of attached drugs can often be more precisely controlled. Drugs with narrow therapeutic windows can be designed to maintain more desirable and stable levels in the blood. The technology is not limited to pendent POZ. Linear POZ can also be applied to proteins, aptamers and other classes of molecules.

POZ delivers key advantages

POZ is engineered to address the limitations of PEG (polyethylene glycol) and other biocompatible polymers – such as immunogenicity, where unlike PEG, POZ does not elicit an immune response or stimulate development of antibodies to the polymer itself.

How Pendent POZ Works

ENABLING CONTINUOUS DRUG DELIVERY and why it matters
Many drugs, for example those used to treat neurological disorders like Parkinson’s, have narrow therapeutic ranges in which they can work safely and efficaciously. They are often dosed more frequently – resulting in large and frequent fluctuations in drug exposure. They have to be monitored and dose adjusted with greater frequency, and on an individual basis. These fluctuations present clinical, compliance and quality of life challenges for many patients.

How We Make Pendent POZ

Programmable loading of polymer is determined by the ratio of pentynyl : neutral monomers at initial synthesis (example above is a 20 kDa 10 pendent POZ)

Ion exchange chromatography for purification takes advantage of the – COOH on the terminus of the polymer (Typically > 60% yields, PDI < 1.02)

How We Make Pendent POZ Therapeutics

Programmable loading of polymer during initial synthesis – Controlled drug loading at the “click chemistry” step

Single-step Cu(I)-catalyzed “click chemistry” at pendent alkyne (Scripps Research Institute global exclusive license to Serina)

Drug release is tuned by the nature of the linker attached to the drug (this requires a “chemical handle” for attachment).

A Powerful Platform for Patient Outcomes

POZ changes the treatment paradigm for PARKINSONS DISEASE.

Parkinson’s treatment has not really changed in 50 years. As many as ten million people worldwide may be affected by the disease. Patients with advancing disease frequently develop “OFF” time – their existing medications simply do not allow them to perform even routine activities. They are invariably treated with L-DOPA to control their symptoms and over time invariably develop dyskinesia (involuntary motor fluctuation) due to the phasic peak/trough nature of short acting dopamine drugs.

There is a significant unmet need for continuous dopaminergic stimulation. 

Apomorphine (a dopamine agonist) is the “holy grail” of  dopamine therapy in advanced disease – capable of reversing “OFF” periods within minutes. But the current formulations are confounded by severe skin reactions, and it must be delivered via a continuous subcutaneous electronic infusion device each day. This often requires a health care provider to set it up daily.

SER-252 POZ-apomorphine is a potential breakthrough therapy for advanced disease, delivered as a single injection once a week. 

Reducing “OFF” time, with no adverse skin reactions and no need for a doctor or nurse to administer it. SER-252 is a preventive therapy (not a rescue therapy) with the potential to increase “ON” time, prevent dyskinesia, and may allow some patients to titrate off all L-DOPA.

Publications List